Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Loser

Pharmacyclics Incorporated ( PCYC) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.9%. By the end of trading, Pharmacyclics Incorporated fell $1.46 (-2.7%) to $53.05 on average volume. Throughout the day, 1.3 million shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in price between $51.38-$54.21 after having opened the day at $52.93 as compared to the previous trading day's close of $54.51. Other company's within the Drugs industry that declined today were: K-V Pharmaceutical Company ( KV.B), down 21.2%, Reliv' International ( RELV), down 13.6%, Ampio Pharmaceuticals ( AMPE), down 12.3%, and ACADIA Pharmaceuticals ( ACAD), down 8.5%.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $3.65 billion and is part of the health care sector. The company has a P/E ratio of 240.3, below the average drugs industry P/E ratio of 264.4 and above the S&P 500 P/E ratio of 17.7. Shares are up 256.7% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and weak operating cash flow.

On the positive front, Opexa Therapeutics ( OPXA), up 86%, Cormedix ( CRMD), up 19.1%, Affymax ( AFFY), up 15.8%, and Cell Therapeutics ( CTIC), up 12.4%, were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015